Thalidomide
Conditions
Keywords
Thalidomide, R-CHOP, diffuse large B-cell lymphoma
Brief summary
The purpose of this study is to evaluate the efficacy of Thalidomide combined with R-CHOP(RT-CHOP) in newly diagnosed，untreated double-expressor Diffuse Large B-Cell Lymphoma patients (DLBCL)
Detailed description
Double expressor lymphoma is a subtype of diffuse large B-cell lymphoma defined as having increased expression of MYC and BCL-2 and/or BCL-6 by immunohistochemistry. Patients with double-expressor lymphomas have a poor prognosis when treated with standard chemoimmunotherapy and have increased risk of progression and recurrence. The investigators conducted this study to evaluate the efficacy of Thalidomide combined with R-CHOP(RT-CHOP) in newly diagnosed double-expressed, untreated Diffuse Large B-Cell Lymphoma patients (DLBCL). Thalidomide is a kind of glutamate derivatives, which can inhibit angiogenesis by blocking bFGF and VEGF, and it can also modulate the immune system by co-stimulating T cell proliferation. In addition, thalidomide can also inhibit the IKK activity and block the activation of NF-kB. In this open-label, randomized, phase III study, we are aiming to compare Thalidomide combined with R-CHOP(RT-CHOP) and R-CHOP in newly diagnosed double-expressor Diffuse Large B-Cell Lymphoma patients (DLBCL), in order to find a potential promising way to treat this subtype of lymphoma.
Interventions
DRUGThalidomide combined with R-CHOP
rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
DRUGR-CHOP
rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
Sponsors
Fudan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age range ≥18 years old 2. Eastern Cooperative Oncology Group performance status 0 to 2; 3. Newly diagnosed, untreated, histological confirmed diffuse large B cell lymphoma, non-GCB subtype, and Myc≥40% as well as Bcl-2≥70% through immunohistochemistry； 4. Measurable disease was defined as at least one lesion ≥1.5 cm in length-diameter and ≥0.5 cm in short-diameter by CT. 5. Patients have written informed consent to participate in the study. 6. Ultrasonic cardiogram showed left ventricle ejection fraction ≥ 50%, EKG showed on signs of myocardial ischemia, with no previous arrhythmia which need pharmacological intervention. 7. White blood cell ≥ 3.5×109/L, absolute neutrophil count ≥ 1.5×109/L，platelet ≥ 80×109/L，hemoglobin ≥ 90 g/L 8. total bilirubin \< 1.5×upper limit of normal(ULN), ALT and AST \< 1.5× ULN 9. serum creatine \<1.5×ULN, and creatinine clearance rate (CCR) ≥ 30 ml/min
Exclusion criteria
1. Presence of CNS involvement 2. Particular kind of DLBCL，such as primary mediastinal/thymic B-cell lymphoma, elderly EBV positive DLBCL, primary cutaneous large B lymphoma. 3. History of myocardial diseases, such as congenital heart disease, pericardial disease, heart failure, myocardial infarction, coronary heart disease, valvular heart disease, myocardosis, arrhythmia. 4. History of severe chronic cutaneous diseases. 5. History of allergic asthma or severe allergic diseases. 6. Uncontrolled hypertension and diabetes. 7. History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix 8. HIV, HCV, or syphilis infection； 9. Presence of active HBV infection（HBV-DNA≥104）； 10. Pregnant or lactating women 11. Previously received organ transplant 12. Having usage of Thalidomide； 13. History of deep vein thrombosis 14. Serious uncontrolled infection 15. Having contraindications to the use of large doses of hormone, such as uncontrolled hyperglycemia, gastric ulcer, mental disorder. 16. Severe neurol of mental illness, including dementia and epilepsy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3 year PFS | 3 years | 3 year progression free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 6 weeks，12 weeks，18weeks | overall response rate |
| OS | 3 years | overall survival |
| adverse event | throughout the treatment period，up to 6 months | adverse event related to treatment |
Countries
China
Contacts
Primary ContactFang-Fang Lv
Outcome results
None listed